Fennec Pharmaceuticals (TSE:FRX) Shares Pass Above 50-Day Moving Average - Time to Sell?

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$10.27 and traded as high as C$11.90. Fennec Pharmaceuticals shares last traded at C$11.89, with a volume of 902 shares trading hands.

Fennec Pharmaceuticals Price Performance

The firm has a market capitalization of C$224.09 million, a PE ratio of -196.84 and a beta of 0.25. The business has a 50-day moving average of C$10.37 and a 200 day moving average of C$9.34. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Jeffrey Hackman bought 15,000 shares of the stock in a transaction dated Monday, May 19th. The shares were bought at an average cost of C$9.77 per share, for a total transaction of C$146,580.00. Also, Director Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of C$11.71, for a total value of C$117,096.00. In the last three months, insiders sold 38,076 shares of company stock valued at $391,650. 16.20% of the stock is owned by insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.